<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23388">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01917513</url>
  </required_header>
  <id_info>
    <org_study_id>G-EYE 15505</org_study_id>
    <nct_id>NCT01917513</nct_id>
  </id_info>
  <brief_title>Prospective Trial to Compare the Clinical Efficiency of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy</brief_title>
  <official_title>Prospective Randomized Trial to Compare the Clinical Efficiency (Adenoma Detection Rate) of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smart Medical Systems Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smart Medical Systems Ltd.</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <authority>United Kingdom: National Health Service</authority>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the adenoma detection rate of G-EYE™ high definition
      colonoscopy with that of standard high definition colonoscopy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, two-arm, randomized, open-label study intended to compare the
      detection rate obtained by performing G-EYE™ high definition colonoscopy vs. the detection
      rate obtained by performing high definition standard colonoscopy.

      The study will enroll 1000 subjects. Consecutive adult subjects who were referred for
      elective colonoscopy will be asked to enroll into this randomized clinical study if the
      candidate meets the study inclusion and exclusion criteria.

      Subjects will sign informed consent form and undergo randomization.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>G-EYE™ colonoscopy detection rate of adenomas and serrated lesions compared to the standard colonoscopy detection rate of the same.</measure>
    <time_frame>Approximalty following 14 days (histology results)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of polyp and adenoma detection, procedure times and safety (number of patients with adverse events.</measure>
    <time_frame>Up to 14 days (histology results)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The secondary outcome is a composite-each of the measured parameters will be reported as a single value for each arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Adenoma</condition>
  <condition>Polyps</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>G-EYE™ colonoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-EYE™ colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Colonoscopy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Colonoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>G-EYE™ colonoscopy</intervention_name>
    <description>G-EYE™ colonoscopy</description>
    <arm_group_label>G-EYE™ colonoscopy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Colonoscopy</intervention_name>
    <description>Standard Colonoscopy</description>
    <arm_group_label>Standard Colonoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients over 50 years old

          2. Referred to colonoscopy for screening, following positive FOBT testing, change of
             bowel habits or for surveillance colonoscopy (history of adenoma resection).

          3. The patient must understand and provide written consent for the     procedure.

        Exclusion Criteria:

          1. Subjects with inflammatory bowel disease;

          2. Subjects with a personal history of polyposis syndrome;

          3. Subjects with suspected chronic stricture potentially precluding complete
             colonoscopy;

          4. Subjects with diverticulitis or toxic megacolon;

          5. Subjects with a history of radiation therapy to abdomen or pelvis;

          6. Pregnant or lactating female subjects;

          7. Subjects who are currently enrolled in another clinical investigation.

          8. Subjects with current oral or parenteral use of anticoagulants

          9. Subjects with recent (within the last 3 mounts) coronary ischemia or CVA (stroke)

         10. Any patient condition deemed too risky for the study by the investigator

         11. Previous colonic surgery (except for appendectomy)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Kiesslich, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Marienkrankenhaus Frankfurt, Frankfurt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralf Kiesslich, Prof.</last_name>
    <phone>(069) 1563-1287</phone>
    <email>R.Kiesslich@katharina-kasper.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Harlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jacob Hendel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Thielsen, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Erlangen-Nuremberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helmut Neumann, Prof.</last_name>
      <email>Helmut.Neumann@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Helmut Neumann, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Marienkrankenhaus Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60318</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf Kiesslich, Prof.</last_name>
      <phone>(069) 1563-1287</phone>
      <email>R.Kiesslich@katharina-kasper.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Kiesslich, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur Hoffman, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia Epshtein, Dr.</last_name>
      <phone>972-2-6776951</phone>
      <email>juliae@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Julia Epshtein, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>COPERNICUS Podmiot Leczniczy Sp. z o.o. (Ltd.)</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marek Dobosz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo Suárez González, Dr.</last_name>
      <phone>985108000</phone>
      <phone_ext>38392</phone_ext>
      <email>adolfo.suarez@hcabuenes.es</email>
    </contact>
    <investigator>
      <last_name>Adolfo Suárez González, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Russells Hall Hospital</name>
      <address>
        <city>Dudley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sauid Ishaq, Dr.</last_name>
      <phone>+44 1384 456111</phone>
      <email>Sauid.Ishaq@dgh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sauid Ishaq, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenoma</keyword>
  <keyword>Polyps</keyword>
  <keyword>CRC</keyword>
  <keyword>Colonoscopy</keyword>
  <keyword>Detection Yield</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
